IDWEEK 2017 – Adult Infectious Diseases

Effective treatment of latent tuberculosis infection is key to TB control efforts and approaching the goal of TB elimination, the authors reported.

Study patients were randomized to 1-hour IV fosfomycin 6g infusion every 8 hours (18 g total daily dose) or IV piperacillin/tazobactam 4.5g infused over 1 hour every 8 hours for a fixed 7 days.

Researchers compared the integrated safety outcomes between delafloxacin and vancomycin/aztreonam from two Phase 3 ABSSSI studies.

Clinical and demographic profiles of patients were compared on those who completed the 9H vs. 3HP regimens with a focus on adverse events, which can commonly cause treatment discontinuation.

The ceftriaxone + doxycycline regimen has been favored in light of ‘recent concerns of increased cardiovascular risk associated with azithromycin

The researchers compared the effectiveness of oral beta-lactams to fluoroquinolones in the treatment of Enterobacteriaceae bloodstream infections (EBSI) in adult patients.

Intravenous (IV) antibiotics such as CPT is indicated for ABSSSIs “but real world clinical comparative data is limited.”

To investigate the efficacy of telavancin in the treatment of bacteremia and infective endocarditis, the authors looked at data from the Telavancin Observational Use Registry, which reports on outcomes of patients treated with telavancin in clinical practice.

A total of 1,042 patients with infection were randomly assigned to receive either intravenous/oral DLX monotherapy or VAN (15mg/kg) with AZ for 5 to 14 days.

Participants included 464 hospitalized adults with cUTI or AP diagnosis, randomly assigned to be administered either ZTI-01 or piperacillin/tazobactam for a fixed 7 days.